Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Encequidar mesylate + paclitaxel by Hanmi Pharmaceuticals for Breast Cancer: Likelihood of Approval
Encequidar mesylate + paclitaxel is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Breast Cancer. According...